Global CRO Merged with P95 to form a leading global CRO with integrated expertise across neuroscience, cardio-renal-metabolic, and infectious diseases and vaccines, indicating expanded service breadth and international footprint ripe for cross-sell to CNS and cardiometabolic clients.

Leadership Pivot Recent CEO appointment and ongoing leadership additions signal strategic growth and renewed focus on scalable operations, presenting an opportunity to engage in executive-level conversations about expanded programs and strategic partnerships.

Specialized Focus Known strength in CNS and rare diseases with strong site networks and investigator engagement, enabling targeted outreach to biotechnology and pharma companies pursuing CNS, neurodegenerative, and cardio-metabolic trials seeking efficient patient recruitment.

Financial Health Revenue in the tens of millions range with mid-size employee base, suggesting a buyers’ window for mid-scale trials and flexible pricing models, plus opportunities to upsell larger, multi-therapy programs through the expanded Julius Clinical platform.

Strategic Partnerships Active collaborations with Esperion and regional partners, plus integration with global networks, creating openings for co-development, late-stage programs, and joint ventures in high-priority therapy areas.